naltrexone and Smoking Cessation

naltrexone has been researched along with Smoking Cessation in 70 studies

Research

Studies (70)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (4.29)	18.2507
2000's	35 (50.00)	29.6817
2010's	28 (40.00)	24.3611
2020's	4 (5.71)	2.80

Authors

Authors	Studies
Albuquerque, EX; Almeida, LE; Camara, AL; Maelicke, A; Pereira, EF	1
Green, R; Montoya, AK; Ray, LA	1
Andale, T; Aruasa, WK; Gakinya, B; Jaguga, F; Kerema, J; Kinyanjui, D; Kirwa, P; Kwobah, C; Kwobah, EK; Manji, I; Mwangi, F; Songok, J; Temet, E; Werunga, K	1
Aguilar-Salinas, C; Benchimol, A; Bonilha, I; Carvalho, LSF; Cercato, C; Geloneze, B; Hohl, A; Luchiari, B; Moura, F; Nadruz, W; Sposito, AC	1
Enders, C; Green, R; Grodin, EN; Hartwell, E; Ho, D; Leventhal, AM; Li, G; Lim, A; Meredith, L; Miotto, K; Nieto, SJ; Ray, LA; Shoptaw, S; Venegas, A	1
Brown, RA; Cioe, PA; Kahler, CW; Leggio, L; O'Malley, SS; Ramsey, SE; Spillane, NS; Tzilos, GK	1
Cioe, PA; Kahler, CW; Lechner, WV; Sidhu, NK	1
Achenbach, C; Akanbi, MO; Bilaver, LA; Carroll, AJ; Hitsman, B; Jordan, N; McHugh, MC; Murphy, R; O'Dwyer, LC	1
Lim, AC; Ray, LA; Roche, DJO	1
Bujarski, S; Green, R; Lim, AC; Ray, LA; Venegas, A	1
Ahsan, H; Argos, M; Jasmine, F; Kibriya, MG; King, AC; Roche, DJO; Trela, CJ	1
Gorelick, DA; Mannelli, P; Peindl, KS; Wu, LT	1
Cao, D; King, A; Rueger, SY; Zhang, L	1
Douaihy, AB; Kelly, TM; Sullivan, C	1
David, SP; Evins, AE; Lancaster, T; Prochaska, JJ; Stead, LF	1
Chu, IM; David, SP; Evins, AE; Lancaster, T; Prochaska, JJ; Stead, LF	1
Brody, A; Courtney, KE; Ghahremani, DG; London, ED; Miotto, K; Ray, LA	2
Jatlow, PI; Mayne, ST; O'Malley, SS; Wu, R	1
Bujarski, S; Ray, LA	1
Cao, D; Fridberg, DJ; Grant, JE; King, AC	1
Bress, A; Hooker, SE; King, A; Kittles, R; Wing, C	1
Bujarski, S; Green, R; Hartwell, E; Ray, LA; Roche, DJ	1
Kahler, CW; Knopik, VS; Lechner, WV; Leventhal, AM; McGeary, JE; McKee, SA; Metrik, J; Rohsenow, DJ; Spillane, NS; Tidey, JW	1
Allen, S; Grabowski, J; Hatsukami, DK; Mooney, ME; Oliver, A; Pentel, P; Schmitz, JM	1
Capurso, NA	1
Epstein, A; King, A; Munisamy, G; Walsh, Z	1
Cooney, JL; Cooney, NL; McKee, SA; O'Malley, SS; Toll, BA	1
Cooney, NL; Krishnan-Sarin, S; Leeman, RF; Makuch, RW; McKee, SA; Meandzija, B; O'Malley, SS; Wu, R	1
McKee, SA	1
Cao, D; King, A; Vanier, C; Wilcox, T	1
Andrade, AG; Baltieri, DA; Daró, FR; Ribeiro, PL	1
Burnand, B; Nanchen, D; Peytremann-Bridevaux, I; Walther, MR; Willi, C	1
Billes, SK; Dunayevich, E; Erickson, JS; Katz, BB; Oskooilar, N; Tollefson, G; Wilcox, CS	1
Berrendero, F; Maldonado, R; Martín-García, E; Robledo, P; Trigo, JM	1
Jatlow, P; Makuch, R; Meandzija, B; O'Malley, SS; Toll, BA; White, M; Wu, R	1
Amin, Z; Czarkowski, KA; Epperson, CN; Jatlow, P; Mazure, CM; O'Malley, SS; Toll, B; Wu, R	1
Cai, X; Cao, D; deWit, H; King, AC; Kranzler, HR; Matthews, AK; O'Malley, SS; Stachoviak, RJ	1
Cao, D; King, AC; O'Malley, SS; Zhang, L	1
Frost, JJ; Kuwabara, H; McCaul, ME; Wand, GS; Weerts, EM; Wong, DF; Xu, X	1
King, AC	1
Abrams, DB; Colby, SM; Gulliver, SB; Monti, PM; Rohsenow, DJ; Swift, RM	1
Ahmadi, J; Ahmadi, M; Ahmadi, N; Ashkani, H	1
Epstein, AM; King, AC	1
Krishnan-Sarin, S; Meandzija, B; O'Malley, S	1
Kosten, TR; Sofuoglu, M	1
Jepson, C; Lerman, C; Lynch, KG; Patterson, F; Perkins, K; Rukstalis, M; Strasser, A	1
Byars, JA; Frost-Pineda, K; Gold, MS; Jacobs, WS	1
Cooney, NL; McKee, SA; O'Malley, SS; Toll, BA	1
Breteler, MH; Kerkhof, AJ; Postmus, PE; Roozen, HG; Van Beers, SE; Weevers, HJ; Willemsen, MC	1
Blakeslee, A; Cooney, JL; Cooney, NL; Dubin, JA; Jatlow, P; Krishnan-Sarin, S; Makuch, R; McKee, SA; Meandzija, B; O'Malley, SS; Romano-Dahlgard, D; Wu, R	1
Crooks, PA; Hamad, MO; Kiptoo, PK; Stinchcomb, AL	1
Berrettini, WH; Jepson, C; Lerman, C; Lynch, KG; O'Malley, S; Patterson, F; Perkins, K; Ray, R; Rukstalis, M; Strasser, A	1
Cao, D; de Wit, H; Hatsukami, D; King, A; Niaura, R; Riley, RC	1
David, S; Evins, AE; Lancaster, T; Stead, LF	1
Diehl, A; Mann, K	1
McKee, SA; O'malley, SS; White, MA	1
Jatlow, P; Martin, DJ; McKee, SA; O'Malley, SS; Toll, BA	1
Hutchison, KE; Kahler, CW; Leventhal, AM; Miranda, R; Monti, PM; Ray, LA; Swift, R	1
Katulak, NA; O'Malley, S; Toll, BA; Williams-Piehota, P	1
Leary, V; Meandzija, B; O'Malley, SS; Salovey, P; Toll, BA; Wu, R	1
Crooks, PA; Hamad, MO; Hammell, DC; Kiptoo, PK; Paudel, KS; Stinchcomb, AL	1
Tyndale, R	1
Lerner, AG; Oyffe, I; Sigal, M	1
Covey, LS; Glassman, AH; Stetner, F	1
Croghan, GA; Croghan, IT; Hurt, RD; Offord, KP; Wolter, TD; Wong, GY	1
King, AC; Meyer, PJ	1
Albuquerque, EX; Alkondon, M; Almeida, LE; Fawcett, WP; Pereira, EF; Randall, WR	1
David, S; Lancaster, T; Stead, LF	1
Golding, M; Hatsukami, DK; Jamerson, BD; Kotlyar, M	1

Reviews

12 review(s) available for naltrexone and Smoking Cessation

Article	Year
Cardiovascular safety of naltrexone and bupropion therapy: Systematic review and meta-analyses. Obesity reviews : an official journal of the International Association for the Study of Obesity, 2021, Volume: 22, Issue:6 Topics: Bupropion; Child; Female; Humans; Male; Naltrexone; Randomized Controlled Trials as Topic; Smoking Cessation; Tobacco Use Cessation Devices; Weight Loss	2021
The efficacy of smoking cessation interventions in low- and middle-income countries: a systematic review and meta-analysis. Addiction (Abingdon, England), 2019, Volume: 114, Issue:4 Topics: Adult; Behavior Therapy; Bupropion; Cigarette Smoking; Clonidine; Counseling; Developing Countries; Humans; Mobile Applications; Naltrexone; Nortriptyline; Randomized Controlled Trials as Topic; Smoking Cessation; Smoking Cessation Agents; Tobacco Use Cessation Devices; Varenicline	2019
Medications for substance use disorders. Social work in public health, 2013, Volume: 28, Issue:3-4 Topics: Alcohol Deterrents; Alcoholism; Analgesics, Opioid; Behavior Therapy; Behavior, Addictive; Buprenorphine; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Secondary Prevention; Smoking Cessation; Substance Withdrawal Syndrome; Substance-Related Disorders; Tobacco Use Disorder	2013
Opioid antagonists for smoking cessation. The Cochrane database of systematic reviews, 2013, Jun-06, Issue:6 Topics: Buprenorphine; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Smoking; Smoking Cessation; Tobacco Use Cessation Devices	2013
Systematic review and meta-analysis of opioid antagonists for smoking cessation. BMJ open, 2014, Mar-14, Volume: 4, Issue:3 Topics: Adult; Humans; Naltrexone; Narcotic Antagonists; Smoking; Smoking Cessation; Tobacco Use Cessation Devices	2014
Developing human laboratory models of smoking lapse behavior for medication screening. Addiction biology, 2009, Volume: 14, Issue:1 Topics: Alcohol Drinking; Arousal; Bupropion; Cues; Drug Evaluation, Preclinical; Humans; Models, Psychological; Motivation; Naltrexone; Nicotine; Psychotropic Drugs; Secondary Prevention; Smoking; Smoking Cessation; Smoking Prevention; Social Environment; Social Facilitation; Tobacco Use Disorder	2009
Neurobiological mechanisms involved in nicotine dependence and reward: participation of the endogenous opioid system. Neuroscience and biobehavioral reviews, 2010, Volume: 35, Issue:2 Topics: Animals; Behavior, Addictive; Humans; Motivation; Naltrexone; Neurotransmitter Agents; Nicotine; Opioid Peptides; Receptors, Nicotinic; Reinforcement, Psychology; Reward; Smoking Cessation; Tobacco Use Disorder	2010
Pharmacologic management of relapse prevention in addictive disorders. The Psychiatric clinics of North America, 2004, Volume: 27, Issue:4 Topics: Administration, Cutaneous; Administration, Oral; Alcohol Deterrents; Alcoholism; Behavior, Addictive; Disulfiram; Humans; Naltrexone; Narcotics; Nicotine; Smoking Cessation; Smoking Prevention; Substance-Related Disorders	2004
Opioid antagonists for smoking cessation. The Cochrane database of systematic reviews, 2006, Oct-18, Issue:4 Topics: Buprenorphine; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Smoking; Smoking Cessation	2006
[Pharmacological relapse prevention in alcohol and tobacco dependence]. Der Internist, 2007, Volume: 48, Issue:1 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Combined Modality Therapy; Disulfiram; Humans; Naltrexone; Nicotine; Psychotherapy; Secondary Prevention; Smoking Cessation; Substance Withdrawal Syndrome; Taurine; Tobacco Use Disorder	2007
Opioid antagonists for smoking cessation. The Cochrane database of systematic reviews, 2001, Issue:3 Topics: Buprenorphine; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Smoking; Smoking Cessation	2001
Effect of nonnicotine pharmacotherapy on smoking behavior. Pharmacotherapy, 2001, Volume: 21, Issue:12 Topics: Amphetamines; Bupropion; Clonidine; Doxepin; Humans; Naltrexone; Nortriptyline; Selective Serotonin Reuptake Inhibitors; Smoking Cessation	2001

Trials

40 trial(s) available for naltrexone and Smoking Cessation

Article	Year
Efficacy of Combining Varenicline and Naltrexone for Smoking Cessation and Drinking Reduction: A Randomized Clinical Trial. The American journal of psychiatry, 2021, 09-01, Volume: 178, Issue:9 Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Cholinergic Agonists; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Smoking Cessation; Smoking Cessation Agents; Varenicline	2021
A Double-Blind Randomized Placebo-Controlled Trial of Oral Naltrexone for Heavy-Drinking Smokers Seeking Smoking Cessation Treatment. Alcoholism, clinical and experimental research, 2017, Volume: 41, Issue:6 Topics: Administration, Oral; Adult; Alcohol Drinking; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Acceptance of Health Care; Smoking; Smoking Cessation; Tobacco Use Cessation Devices; Treatment Outcome	2017
Effects of time-varying changes in tobacco and alcohol use on depressive symptoms following pharmaco-behavioral treatment for smoking and heavy drinking. Drug and alcohol dependence, 2019, 01-01, Volume: 194 Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Behavior Therapy; Depression; Female; Humans; Male; Middle Aged; Naltrexone; Smoking Cessation; Time Factors; Tobacco Smoking; Tobacco Use Disorder	2019
Naltrexone and alcohol effects on craving for cigarettes in heavy drinking smokers. Experimental and clinical psychopharmacology, 2019, Volume: 27, Issue:3 Topics: Adult; Alcohol Drinking; Alcoholism; Breath Tests; Craving; Double-Blind Method; Drug Interactions; Ethanol; Female; Humans; Male; Naltrexone; Smokers; Smoking; Smoking Cessation; Tobacco Products; Young Adult	2019
Smoking and opioid detoxification: behavioral changes and response to treatment. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2013, Volume: 15, Issue:10 Topics: Adult; Double-Blind Method; Female; Humans; Male; Naltrexone; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder	2013
Effects of the opioid receptor antagonist naltrexone on smoking and related behaviors in smokers preparing to quit: a randomized controlled trial. Addiction (Abingdon, England), 2013, Volume: 108, Issue:10 Topics: Adult; Alcohol Drinking; Behavior, Addictive; Chicago; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Smoking; Smoking Cessation; Treatment Outcome	2013
Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings. Psychopharmacology, 2014, Volume: 231, Issue:19 Topics: Adult; Alcohol Drinking; Benzazepines; Craving; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Varenicline; Young Adult	2014
Smoking cessation is followed by increases in serum bilirubin, an endogenous antioxidant associated with lower risk of lung cancer and cardiovascular disease. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2014, Volume: 16, Issue:8 Topics: Administration, Cutaneous; Adult; Antioxidants; Bilirubin; Cardiovascular Diseases; Counseling; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Naltrexone; Nicotine; Risk Factors; Smoking; Smoking Cessation; Tobacco Use Cessation Devices; Treatment Outcome	2014
Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings. The American journal of drug and alcohol abuse, 2015, Volume: 41, Issue:1 Topics: Adult; Alcoholism; Benzazepines; Brain; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Treatment Outcome; Varenicline	2015
Negative affect is associated with alcohol, but not cigarette use in heavy drinking smokers. Addictive behaviors, 2014, Volume: 39, Issue:12 Topics: Adult; Affect; Alcohol-Related Disorders; Benzazepines; Comorbidity; Craving; Cross-Sectional Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Psychiatric Status Rating Scales; Quinoxalines; Smoking; Smoking Cessation; Varenicline; Young Adult	2014
Naltrexone improves quit rates, attenuates smoking urge, and reduces alcohol use in heavy drinking smokers attempting to quit smoking. Alcoholism, clinical and experimental research, 2014, Volume: 38, Issue:10 Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Dose-Response Relationship, Drug; Double-Blind Method; Drinking Behavior; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Prevalence; Smoking; Smoking Cessation; Smoking Prevention; Time Factors; Treatment Outcome	2014
Combined varenicline and naltrexone treatment reduces smoking topography intensity in heavy-drinking smokers. Pharmacology, biochemistry, and behavior, 2015, Volume: 134 Topics: Adult; Alcohol Drinking; Double-Blind Method; Female; Humans; Male; Naltrexone; Smoking; Smoking Cessation; Varenicline	2015
Bupropion and naltrexone for smoking cessation: A double-blind randomized placebo-controlled clinical trial. Clinical pharmacology and therapeutics, 2016, Volume: 100, Issue:4 Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Patient Compliance; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Treatment Outcome; Young Adult	2016
The impact of depressive symptoms on the efficacy of naltrexone in smoking cessation. Journal of addictive diseases, 2008, Volume: 27, Issue:1 Topics: Administration, Cutaneous; Adult; Combined Modality Therapy; Counseling; Depression; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Personality Inventory; Smoking Cessation; Treatment Outcome	2008
Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. The international journal of neuropsychopharmacology, 2009, Volume: 12, Issue:5 Topics: Adult; Alcohol Drinking; Alcoholism; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Naltrexone; Smoking; Smoking Cessation	2009
Naltrexone decreases heavy drinking rates in smoking cessation treatment: an exploratory study. Alcoholism, clinical and experimental research, 2009, Volume: 33, Issue:6 Topics: Adult; Alanine Transaminase; Alcohol Drinking; Aspartate Aminotransferases; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Liver; Male; Naltrexone; Narcotic Antagonists; Smoking; Smoking Cessation; Treatment Outcome	2009
Effects of topiramate or naltrexone on tobacco use among male alcohol-dependent outpatients. Drug and alcohol dependence, 2009, Nov-01, Volume: 105, Issue:1-2 Topics: Adolescent; Adult; Alcoholism; Analysis of Variance; Anticonvulsants; Dose-Response Relationship, Drug; Double-Blind Method; Fructose; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Outpatients; Patient Compliance; Secondary Prevention; Smoking; Smoking Cessation; Socioeconomic Factors; Topiramate; Treatment Outcome; Young Adult	2009
An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. Addictive behaviors, 2010, Volume: 35, Issue:3 Topics: Adult; Bupropion; Cotinine; Counseling; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Obesity; Overweight; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Treatment Outcome; Weight Gain	2010
Low-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: a randomized trial. Drug and alcohol dependence, 2010, Oct-01, Volume: 111, Issue:3 Topics: Administration, Cutaneous; Adult; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Nicotine; Prospective Studies; Smoking; Smoking Cessation; Weight Gain	2010
Exploring the impact of gender and reproductive status on outcomes in a randomized clinical trial of naltrexone augmentation of nicotine patch. Drug and alcohol dependence, 2010, Nov-01, Volume: 112, Issue:1-2 Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Body Weight; Female; Humans; Interviews as Topic; Male; Medication Adherence; Menstrual Cycle; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Sex Characteristics; Smoking Cessation; Treatment Outcome; Young Adult	2010
Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women. Journal of clinical psychopharmacology, 2012, Volume: 32, Issue:5 Topics: Administration, Oral; Adult; Cognitive Behavioral Therapy; Combined Modality Therapy; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Sex Factors; Smoking Cessation; Time Factors; Tobacco Use Cessation Devices; Tobacco Use Disorder; Treatment Outcome; Weight Gain	2012
Naltrexone reduction of long-term smoking cessation weight gain in women but not men: a randomized controlled trial. Biological psychiatry, 2013, May-01, Volume: 73, Issue:9 Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Sex Factors; Smoking Cessation; Treatment Outcome; Weight Gain	2013
Role of naltrexone in initial smoking cessation: preliminary findings. Alcoholism, clinical and experimental research, 2002, Volume: 26, Issue:12 Topics: Adult; Alcohol Drinking; Double-Blind Method; Humans; Middle Aged; Naltrexone; Smoking; Smoking Cessation	2002
Naltrexone treatment for alcoholics: effect on cigarette smoking rates. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2003, Volume: 5, Issue:2 Topics: Adult; Alcoholism; Analysis of Variance; Female; Health Promotion; Humans; Incidence; Male; Naltrexone; Narcotic Antagonists; Smoking; Smoking Cessation; Time Factors; Treatment Outcome	2003
Twenty-four week maintenance treatment of cigarette smoking with nicotine gum, clonidine and naltrexone. Journal of substance abuse treatment, 2003, Volume: 24, Issue:3 Topics: Adult; Antihypertensive Agents; Chewing Gum; Clonidine; Double-Blind Method; Humans; Iran; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Prospective Studies; Smoking; Smoking Cessation; Smoking Prevention; Time Factors	2003
Naltrexone attenuates acute cigarette smoking behavior. Pharmacology, biochemistry, and behavior, 2004, Volume: 77, Issue:1 Topics: Adult; Aged; Analysis of Variance; Choice Behavior; Female; Humans; Male; Middle Aged; Naltrexone; Smoking; Smoking Cessation	2004
Naltrexone and nicotine patch smoking cessation: a preliminary study. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2003, Volume: 5, Issue:6 Topics: Administration, Cutaneous; Adult; Female; Ganglionic Stimulants; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Placebos; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome	2003
Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm. Psychopharmacology, 2005, Volume: 180, Issue:1 Topics: Adolescent; Adult; Aged; Bupropion; Choice Behavior; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Reinforcement, Psychology; Smoking Cessation; Tobacco Use Disorder	2005
Naltrexone augments the effects of nicotine replacement therapy in female smokers. Journal of addictive diseases, 2005, Volume: 24, Issue:2 Topics: Administration, Cutaneous; Administration, Topical; Adult; Combined Modality Therapy; Double-Blind Method; Female; Humans; Naltrexone; Narcotic Antagonists; Nicotine; Psychotherapy; Smoking; Smoking Cessation; Smoking Prevention; Tobacco Use Disorder	2005
Do daily interactive voice response reports of smoking behavior correspond with retrospective reports? Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors, 2005, Volume: 19, Issue:3 Topics: Data Collection; Double-Blind Method; Female; Humans; Male; Mental Recall; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Patient Compliance; Self Disclosure; Sensitivity and Specificity; Smoking; Smoking Cessation; Telephone; Time Factors	2005
Effects on smoking cessation: naltrexone combined with a cognitive behavioral treatment based on the community reinforcement approach. Substance use & misuse, 2006, Volume: 41, Issue:1 Topics: Adult; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Netherlands; Pneumothorax; Smoking Cessation; Tobacco Use Disorder	2006
A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. Archives of internal medicine, 2006, Mar-27, Volume: 166, Issue:6 Topics: Administration, Cutaneous; Administration, Oral; Ambulatory Care; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Linear Models; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Nicotinic Agonists; Smoking Cessation; Substance Withdrawal Syndrome; Surveys and Questionnaires; Treatment Outcome; Weight Gain	2006
Association of OPRM1 A118G variant with the relative reinforcing value of nicotine. Psychopharmacology, 2006, Volume: 188, Issue:3 Topics: Adaptation, Psychological; Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Polymorphism, Genetic; Receptors, Opioid, mu; Reinforcement, Psychology; Risk Factors; Sex Factors; Smoking; Smoking Cessation; Substance Withdrawal Syndrome	2006
Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2006, Volume: 8, Issue:5 Topics: Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Sex Characteristics; Smoking Cessation; Treatment Outcome	2006
Smoke and mirrors: magnified beliefs that cigarette smoking suppresses weight. Addictive behaviors, 2007, Volume: 32, Issue:10 Topics: Adult; Culture; Feeding Behavior; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Overweight; Psychiatric Status Rating Scales; Self Concept; Smoking; Smoking Cessation; Weight Gain	2007
Pharmacological effects of naltrexone and intravenous alcohol on craving for cigarettes among light smokers: a pilot study. Psychopharmacology, 2007, Volume: 193, Issue:4 Topics: Adult; Alcoholic Intoxication; Behavior, Addictive; Breath Tests; Central Nervous System Depressants; Double-Blind Method; Drug Interactions; Ethanol; Female; Humans; Injections, Intravenous; Male; Naltrexone; Narcotic Antagonists; Pilot Projects; Smoking; Smoking Cessation	2007
Validation of a scale for the assessment of food cravings among smokers. Appetite, 2008, Volume: 50, Issue:1 Topics: Administration, Cutaneous; Appetite; Dietary Fats; Dietary Sucrose; Female; Food Preferences; Humans; Male; Naltrexone; Nicotine; Placebos; Reproducibility of Results; Smoking; Smoking Cessation; Surveys and Questionnaires; Taste; Weight Gain	2008
Naltrexone effects on short-term and long-term smoking cessation. Journal of addictive diseases, 1999, Volume: 18, Issue:1 Topics: Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Smoking Cessation; Time Factors; Tobacco Use Disorder	1999
A randomized trial of naltrexone for smoking cessation. Addiction (Abingdon, England), 1999, Volume: 94, Issue:8 Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Aged; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Nicotinic Agonists; Smoking Cessation	1999
Naltrexone alteration of acute smoking response in nicotine-dependent subjects. Pharmacology, biochemistry, and behavior, 2000, Volume: 66, Issue:3 Topics: Adult; Affect; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder	2000

Other Studies

18 other study(ies) available for naltrexone and Smoking Cessation

Article	Year
Sensitivity of neuronal nicotinic acetylcholine receptors to the opiate antagonists naltrexone and naloxone: receptor blockade and up-regulation. Bioorganic & medicinal chemistry letters, 2004, Apr-19, Volume: 14, Issue:8 Topics: Cell Line; Gene Expression; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Neurons; Nicotine; Patch-Clamp Techniques; Receptors, Nicotinic; Sensitivity and Specificity; Smoking Cessation; Structure-Activity Relationship; Time Factors; Up-Regulation	2004
The relationship between drinking and smoking in a clinical trial for smoking cessation and drinking reduction. Experimental and clinical psychopharmacology, 2022, Volume: 30, Issue:6 Topics: Alcohol Drinking; Naltrexone; Smoking; Smoking Cessation; Treatment Outcome; Varenicline	2022
Intravenous ketamine for severe alcohol use disorder at Moi Teaching & Referral Hospital, Kenya: a case report. Substance abuse treatment, prevention, and policy, 2023, 02-17, Volume: 18, Issue:1 Topics: Adult; Alcoholism; Hospitals; Humans; Kenya; Ketamine; Male; Naltrexone; Referral and Consultation; Smoking Cessation; Tobacco Use Cessation Devices	2023
Distress Tolerance and Craving for Cigarettes Among Heavy Drinking Smokers. Journal of studies on alcohol and drugs, 2018, Volume: 79, Issue:6 Topics: Adult; Alcohol Drinking; Alcoholism; Cigarette Smoking; Craving; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Random Allocation; Smokers; Smoking Cessation; Stress, Psychological; Varenicline; Young Adult	2018
Lack of Association between Opioid-Receptor Genotypes and Smoking Cessation Outcomes in a Randomized, Controlled Naltrexone Trial. Alcohol and alcoholism (Oxford, Oxfordshire), 2019, Jan-09, Volume: 54, Issue:5 Topics: Adult; Female; Genotype; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Polymorphism, Single Nucleotide; Receptors, Opioid; Smoking Cessation; Tobacco Smoking; Treatment Outcome	2019
Genetic ancestry as an effect modifier of naltrexone in smoking cessation among African Americans: an analysis of a randomized controlled trial. Pharmacogenetics and genomics, 2015, Volume: 25, Issue:6 Topics: Adult; Black or African American; Female; Genotype; Humans; Male; Middle Aged; Naltrexone; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic; Smoking; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome; White People	2015
Influence of the A118G Polymorphism of the OPRM1 Gene and Exon 3 VNTR Polymorphism of the DRD4 Gene on Cigarette Craving After Alcohol Administration. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2016, Volume: 18, Issue:5 Topics: Adult; Alcohol Drinking; Alleles; Craving; Exons; Female; Genotype; Humans; Male; Minisatellite Repeats; Naltrexone; Narcotic Antagonists; Polymorphism, Genetic; Receptors, Opioid, mu; Smoking; Smoking Cessation	2016
Naltrexone for the treatment of comorbid tobacco and pornography addiction. The American journal on addictions, 2017, Volume: 26, Issue:2 Topics: Aged; Behavior, Addictive; Erotica; Humans; Male; Naltrexone; Narcotic Antagonists; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome	2017
Correspondence of Interactive Voice Response (IVR) reports of nicotine withdrawal, craving, and negative mood with questionnaire ratings. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2008, Volume: 10, Issue:6 Topics: Adult; Comorbidity; Depression; Female; Humans; Irritable Mood; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Self Disclosure; Self-Assessment; Smoking Cessation; Substance Withdrawal Syndrome; Surveys and Questionnaires	2008
[Preventing weight gain in smoking cessation: there is no miracle solution]. Revue medicale suisse, 2009, Aug-05, Volume: 5, Issue:212 Topics: Adult; Bupropion; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Female; Fluoxetine; Humans; Naltrexone; Narcotic Antagonists; Patient Education as Topic; Risk; Selective Serotonin Reuptake Inhibitors; Smoking Cessation; Substance Withdrawal Syndrome; Weight Gain	2009
Association of smoking with μ-opioid receptor availability before and during naltrexone blockade in alcohol-dependent subjects. Addiction biology, 2014, Volume: 19, Issue:4 Topics: Adult; Alcoholism; Brain; Brain Mapping; Craving; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Positron-Emission Tomography; Receptors, Opioid, mu; Severity of Illness Index; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Cessation Devices; Tobacco Use Disorder	2014
Synthesis and hydrolytic behavior of two novel tripartate codrugs of naltrexone and 6beta-naltrexol with hydroxybupropion as potential alcohol abuse and smoking cessation agents. Bioorganic & medicinal chemistry, 2006, Oct-15, Volume: 14, Issue:20 Topics: Alcohol Deterrents; Bupropion; Drug Stability; Hydrolysis; Molecular Structure; Naltrexone; Smoking Cessation; Stereoisomerism; Structure-Activity Relationship; Time Factors	2006
Factor structure and validity of the Medication Adherence Questionnaire (MAQ) with cigarette smokers trying to quit. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2007, Volume: 9, Issue:5 Topics: Adult; Attitude to Health; Factor Analysis, Statistical; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Nicotine; Patient Compliance; Psychometrics; Reproducibility of Results; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Surveys and Questionnaires; Tobacco Use Disorder	2007
A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain. Addictive behaviors, 2008, Volume: 33, Issue:1 Topics: Adult; Bupropion; Case-Control Studies; Combined Modality Therapy; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Smoking Cessation; Treatment Outcome; Weight Gain	2008
In vivo evaluation of a transdermal codrug of 6-beta-naltrexol linked to hydroxybupropion in hairless guinea pigs. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2008, Apr-23, Volume: 33, Issue:4-5 Topics: Administration, Cutaneous; Alcohol-Related Disorders; Animals; Bupropion; Chromatography, High Pressure Liquid; Drug Delivery Systems; Female; Guinea Pigs; Male; Mass Spectrometry; Molecular Structure; Naltrexone; Prodrugs; Skin; Skin Absorption; Skin Irritancy Tests; Smoking Cessation	2008
Drug addiction: a critical problem calling for novel solutions. Clinical pharmacology and therapeutics, 2008, Volume: 83, Issue:4 Topics: Benzazepines; Buprenorphine; Bupropion; Chronic Disease; Financing, Government; Genetic Testing; Harm Reduction; Humans; Marijuana Smoking; Naltrexone; Narcotic Antagonists; Prevalence; Privacy; Quinoxalines; Receptors, Nicotinic; Recurrence; Risk-Taking; Smoking; Smoking Cessation; Smoking Prevention; Social Environment; Substance-Related Disorders; Varenicline	2008
Naltrexone-induced reduction of tobacco intake. The Journal of clinical psychiatry, 1998, Volume: 59, Issue:1 Topics: Adult; Ambulatory Care; Animals; Comorbidity; Humans; Male; Naltrexone; Opioid-Related Disorders; Smoking; Smoking Cessation; Smoking Prevention	1998
The opioid antagonist naltrexone inhibits activity and alters expression of alpha7 and alpha4beta2 nicotinic receptors in hippocampal neurons: implications for smoking cessation programs. Neuropharmacology, 2000, Volume: 39, Issue:13 Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Cells, Cultured; Electrophysiology; Female; Hippocampus; In Vitro Techniques; Naltrexone; Narcotic Antagonists; Nicotine; Nicotinic Agonists; Patch-Clamp Techniques; Pregnancy; Rats; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Receptors, Nicotinic; Smoking Cessation; Up-Regulation	2000